Table 2.
Quantitative assessment of IC and standard deviation of iodine concentration in PP, AP, and VP.
| Group | NICpro | NICdis | dNIC |
|---|---|---|---|
| PP | |||
| Malignant nodules | (0.67,0.41, 1.19) | (0.43, 0.22, 0.64) | (0.31, 0.11, 0.57) |
| Benign nodules | (0.38, 0.19, 0.82) | (0.53,0.36,1.29) | (-0.26, -0.5, -0.1) |
| P value | 0.037 | 0.093 | p≤0.001 |
| AP | |||
| Malignant nodules | 0.283 ±0.165 | 0.190 ±0.117 | 0.093 ±0.094 |
| Benign nodules | 0.183 ±0.081 | 0.258 ±0.094 | -0.075 ±0.060 |
| P value | 0.012 | 0.024 | p≤0.001 |
| VP | |||
| Malignant nodules | 0.577±0.199 | 0.406±0.142 | 0.171±0.137 |
| Benign nodules | 0.407±0.247 | 0.591±0.247 | -0.183±0.127 |
| P value | 0.005 | 0.004 | p≤0.001 |
PP, pulmonary phase; AP, arterial phase; VP, venous phase; NICpro, normalized iodine concentration in the proximal region; NICdis, normalized iodine concentration in the distal region; dNIC, NICpro-NICdis.